Recruiting
Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer
Title: A prospective multicentric interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of pre-eclampsia in pregnant women who underwent frozen embryo transfer
ClinicalTrials.gov IDNCT05460416
PhasePHASE3
Enrollment276
SponsorCentre Hospitalier Universitaire de Liege
Age18 Years
SexFEMALE
Conditions studied
Embryo Transfer, Hypertension, Pregnancy Induced
About this study
Title: A prospective multicentric interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of pre-eclampsia in pregnant women who underwent frozen embryo transfer
Interventions
- Drug: Acetylsalicylic acid — 160mg once a day
Primary outcomes
- Mean number of women suffering from pre-eclampsia in the treated and not treated groups. (4 years)
Eligibility information
Inclusion Criteria:
* Healthy women from \[18 - 43\] years-old, planned for a frozen embryo transfer, with natural and modified natural or HRT cycle
* Who have given their informed consent
* Who have a confirmed pregnancy at week 6 of amenorrhea.
Exclusion Criteria:
* Women presenting one risk factor for preeclampsia: multiple pregnancy, history of preeclampsia, BMI \> 30, lupus syndrome, preexistent proteinuria, non-treated chronic high blood pressure (\>140/90), antiphospholipid antibody syndrome, diabetes (fasting blood sugar \>126mg/dl)
* Contraindication to acetylsalicylic acid (at risk of active hemorrhage (like hemophilia, …); at risk of or who have a gastro-duodenal ulcer; at risk or how have a terminal renal or hepatic in-sufficiency (only if acetylsalicylic acid is given at high dose)
* Already treated with acetylsalicylic acid
* Treatment with anticoagulants or non-steroid anti-inflammatory drugs
Study locations
- Centre Hospitalier Universitaire de Liège site Citadelle, Liège, Belgium
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.